Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 15;5(7):2212-21.
eCollection 2015.

Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification

Matteo Brunelli  1 , Alessia Nottegar  1 , Giuseppe Bogina  2 , Anna Caliò  1 , Luca Cima  1 , Albino Eccher  1 , Caterina Vicentini  3 , Lisa Marcolini  1 , Aldo Scarpa  4 , Serena Pedron  1 , Eleonora Brunello  1 , Sakari Knuutila  5 , Anna Sapino  6 , Caterina Marchiò  6 , Emilio Bria  7 , Annamaria Molino  7 , Luisa Carbognin  7 , Giampaolo Tortora  7 , Bharat Jasani  8 , Keith Miller  9 , Ibrahim Merdol  9 , Lucia Zanatta  10 , Licia Laurino  10 , Tiina Wirtanen  11 , Giuseppe Zamboni  12 , Marcella Marconi  2 , Marco Chilosi  1 , Erminia Manfrin  1 , Guido Martignoni  1 , Franco Bonetti  1
Affiliations

Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification

Matteo Brunelli et al. Am J Cancer Res. .

Abstract

Monosomy of chromosome 17 may affect the assessment of HER2 amplification. Notably, the prevalence ranges from 1% up to 49% due to lack of consensus in recognition. We sought to investigate the impact of monosomy of chromosome 17 to interpretation of HER2 gene status. 201 breast carcinoma were reviewed for HER2 gene amplification and chromosome 17 status. FISH analysis was performed by using double probes (LSI/CEP). Absolute gene copy number was also scored per each probe. HER2 FISH test was repeated on serial tissue sections, ranging in thickness from 3 to 20 µm. Ratio was scored and subsequently corrected by monosomy after gold control test using the aCGH method to overcome false interpretation due to artefactual nuclear truncation. HER2 immunotests was performed on all cases. 26/201 cases were amplified (13%). Single signals per CEP17 were revealed in 7/201 (3.5%) cases. Five out of 7 cases appeared monosomic with aCGH (overall, 5/201, 2.5%) and evidenced single signals in >60% of nuclei after second-look on FISH when matching both techniques. Among 5, one case showed amplification with a pattern 7/1 (HER2/CEP17>2) of copies (3+ at immunotest); three cases revealed single signals per both probes (LSI/CEP=1) and one case revealed a 3:1 ratio; all last 4 cases showed 0/1+ immunoscore. We concluded that: 1) monosomy of chromosome 17 may be observed in 2.5% of breast carcinoma; 2) monosomy of chromosome 17 due to biological reasons rather than nuclear truncation was observed when using the cut-off of 60% of nuclei harboring single signals; 3) the skewing of the ratio due to single centromeric 17 probe may lead to false positive evaluation; 4) breast carcinomas showing a 3:1 ratio (HER2/CEP17) usually show negative 0/1+ immunoscore and <6 gene copy number at FISH.

Keywords: Breast carcinoma; FISH analysis; HER 2 amplification; aCGH method; chromosome 17; double probes; false positive; monosomy; ratio (HER2/CEP 17); single signals.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Breast carcinoma with monosomy of chromosome 17. Ductal phenotype, luminal A young age (2/5 cases <38 years) (A); triple negative breast carcinoma (2/5 cases) (B); a case of bilateral breast carcinoma (1/5) (C). Four out of five displayed a negative (0 or 1+) HER2 immunoscore (D).
Figure 2
Figure 2
Breast carcinoma with monosomy of chromosome 17. The tumor harbors single signals in >60% of neoplastic nuclei per both LSI Her-2/neu and CEP17 loci at FISH analysis and reveals loss of whole chromosome 17 (type 1 monosomy) after aCGH molecular profiling.
Figure 3
Figure 3
Breast carcinoma with partial monosomy of chromosome 17. The tumor harbors single signals per both LSI Her-2/neu and CEP17 probes in >60% of neoplastic nuclei and evidenced losses of chromosome 17p, CEP17 and the partial chromosome 17q12-21 (type 2 monosomy).
Figure 4
Figure 4
Recommendations’ on Her-2/neu FISH testing when single signals is observed at FISH analysis; when monosomy of chromosome 17 is observed (>60% nuclei with single CEP17 probe), use the single absolute Her-2/neu gene copy number (>6) when distinguishing a case of breast carcinoma with amplification versus not amplified. Type 1 chr17 monosomy reveals loss of whole chromosome 17 whereas type 2 chr17 monosomy show partial losses of chromosome 17 (i.e. loss of 17q, CEP17 and part of 17p).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Risio M, Casorzo L, Redana S, Montemurro F. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep. 2005;13:305–9. - PubMed
    1. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009;10:267–77. - PMC - PubMed
    1. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219:16–24. - PubMed
    1. Starczynski J, Atkey N, Connelly Y, O’Grady T, Campbell FM, di Palma S, Wencyk P, Jasani B, Gandy M, Bartlett JM. HER2 gene amplification in breast cancer: a rogues’ gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol. 2012;137:595–605. - PubMed
    1. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013;31:3997–4013. - PubMed